Scarica l'app Stockscreener
224.13
3.98%
-9.29
Dopo l'orario di chiusura:
225.00
0.87
+0.39%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight - Benzinga
Revolution Medicines jumps on report AbbVie nears takeover - MSN
AbbVie Sues Over Bids To Market Generic Migraine Drugs - Law360
Merck in Talks to Buy Biotech Revolution Medicines, FT Says - Bloomberg.com
Merck in Deal Talks With Biotech Revolution Medicines, FT Says - Bloomberg.com
Key facts: AbbVie revises EPS guidance; negotiates $20B acquisition - TradingView — Track All Markets
AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders - TechStock²
AbbVie Stock Drops After Guidance Update, Wolfe Downgrade And Deal Denial - Benzinga
AbbVie: The Dividend Does Not Lie (NYSE:ABBV) - Seeking Alpha
Merck (MRK) Upgraded by Wolfe Research, AbbVie (ABBV) Downgraded - GuruFocus
AbbVie sees negative Q4 EPS impact from IPR&D expenses - MSN
Merck upgraded, AbbVie downgraded at Wolfe (MRK:NYSE) - Seeking Alpha
AbbVie says it’s not in talks to buy Revolution Medicines; WSJ reports another suitor may prevail - Sherwood News
AbbVie Flags $1.3B Charge, Cuts Fourth-Quarter EPS Outlook - Yahoo Finance
AbbVie, Revolution Medicines Stocks Fall After Drugmaker Denies Takeover Report - Barron's
Aug Big Picture: Can AbbVie Inc. stock continue upward trendDividend Hike & Accurate Trade Setup Notifications - ulpravda.ru
Lockheed, Northrop, Alphabet, Revolution Medicines, AbbVie, Costco, and More Movers - Barron's
Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked inWolfe - Investing.com India
AbbVie (ABBV) Stock Falls After Company Denies Revolution Medicines Buyout Talks - Blockonomi
Northrop, Lockheed, Alphabet, Revolution Medicines, AbbVie, Costco, and More Movers - Barron's
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73 - simplywall.st
Should Health Canada’s Eight-Week MAVIRET Approval Shape AbbVie’s (ABBV) Post-Humira Growth Story? - Yahoo Finance
AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down - TechStock²
Revolution Medicines dips after AbbVie denies takeover talks - TradingView — Track All Markets
AbbVie (ABBV) Stock Drops as Company Denies Revolution Medicines Acquisition Reports - CoinCentral
AbbVie Lowers Q4, 2025 Adjusted EPS Guidance - MarketScreener
Humira Market to Witness Remarkable Growth With AbbVie Inc., Amgen Inc., Samsung Bioepis - openPR.com
AbbVie (ABBV) Projects Q4 Earnings Impact from $1.3 Billion Char - GuruFocus
AbbVie (ABBV) Receives a Buy from Berenberg Bank - The Globe and Mail
AbbVie flags $1.3B IPR&D charge, warns of Q4 earnings pressure (ABBV:NYSE) - Seeking Alpha
Revolution Medicines Stock Pre-Market (-6.0%): AbbVie Denies Acquisition Talks - Trefis
AbbVie Denies Media Reports of Talks to Buy Revolution Medicines - MarketScreener
What's Happening With Cancer Biotech Erasca Shares This Thursday? - Bitget
AbbVie denies media reports of talks to buy Revolution Medicines - WTVB
Exclusive | Revolution Medicines Draws Takeover Interest - The Wall Street Journal
Revolution Medicines Stock Drops After-Hours On AbbVie Denying Acquisition Talks - Stocktwits
Stock Movers: Jeffries, AbbVie, Raytheon - Bloomberg.com
AbbVie2025 adjusted EPS guidance range $9.90$9.94SEC filing - MarketScreener
Revolution Medicines (RVMD) Shares Plunge After AbbVie Denies Acquisition Talks - GuruFocus
Abbvie denies WSJ report of talks to buy biotech player Revolutions Medicine - Crain's Chicago Business
AbbVie (ABBV) Denies Acquisition Talks with Revolution Medicines - GuruFocus
AbbVie (ABBV) Denies Discussions with Revolution Medicines - GuruFocus
AbbVie Says It’s Not in Talks to Buy Revolution Medicines - Bloomberg.com
AbbVie says not in talks to buy Revolution Medicinesreport - MSN
AbbVie reports $1.3 billion Q4 expense from acquired research deals - StreetInsider
Revolution Medicines (RVMD) Surges on AbbVie Acquisition Talks - GuruFocus
AbbVie (ABBV) Nears Acquisition Deal with Revolution Medicines - GuruFocus
Erasca up 66% after WSJ report on AbbVie interest in Revolution Medicines - TipRanks
AbbVie M&A Buzz Sends Revolution Medicines RVMD Above $100, ABBV Stock $230+ - FXLeaders
AbbVie (ABBV) Nears Acquisition of Cancer-Drug Firm Revolution M - GuruFocus
AbbVie (ABBV) Nears Acquisition of Revolution Medicines in a Maj - GuruFocus
American pharmaceutical giant in advanced negotiations for a major acquisition - medwatch.com
Exclusive | AbbVie Near Deal for Revolution MedicinesWSJ - The Wall Street Journal
AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition - MarketScreener
AbbVie in talks to buy biotech Revolution Medicines, WSJ reports - TradingView — Track All Markets
AbbVie in Advanced Talks to Acquire Revolution Medicines - MarketScreener
Revolution Medicines stock surges over 20% on potential AbbVie acquisition By Investing.com - Investing.com UK
AbbVie Close to Deal for Cancer Drugmaker RevMed, WSJ Says - Bloomberg.com
AbbVie, Revolution Medicines said to be close to deal - breakingthenews.net
AbbVie in Advanced Talks to Acquire Revolution Medicines, The Wall Street Journal Reports - MarketScreener
AbbVie in Advanced Discussions to Acquire Revolution Medicines, WSJ Reports - MarketScreener
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73 - Yahoo Finance
UBS Raises AbbVie (ABBV) Price Target to $240 While Maintaining Neutral Rating | ABBV Stock News - GuruFocus
UBS assumes coverage of Abbvie stock with Neutral rating, $240 price target - Investing.com Canada
AbbVie stock nudges higher after Canada clears Maviret — what ABBV investors watch next - TechStock²
0.84%
2.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):